rdus-8k_20210609.htm

RADIUS HEALTH, INC.

Date: June 11, 2021

/s/ Averi Price

Averi Price

General Counsel and Chief Compliance Officer

Delaware		001-35726		80-0145732
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)


22 Boston Wharf Road, 7^th Floor, Boston, MA		02210
(Address of principal executive offices)		(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	RDUS	The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

On June 9, 2021, Radius Health, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 43,060,728 shares of common stock were present in person or represented by proxy at the Annual Meeting, representing approximately 91% of the Company’s outstanding common stock as of April 12, 2021, the record date for the Annual Meeting. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 22, 2021 (the “Proxy Statement”).

Proposal 1 — The following nominees were elected as Class I directors to serve on the Company’s Board of Directors until the 2024 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified, based on the following votes:

Nominee	For	Against	Abstentions	Broker Non-Votes
Owen Hughes	21,658,477	19,186,176	22,745	2,193,330
G. Kelly Martin	35,551,793	5,292,254	23,351	2,193,330

Proposal 2 — The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021, was ratified, based on the following votes:

For		Against		Abstentions		Broker Non-Votes
43,001,783		31,893		27,052		—

Proposal 3 — The compensation of the Company’s named executive officers as disclosed in the Proxy Statement was approved, on an advisory basis, based on the following votes:

For				Against				Abstentions				Broker Non-Votes
	35,276,451				5,553,747				37,200				2,193,330

Proposal 4 — The frequency of future advisory votes on the compensation of the Company’s named executive officers as disclosed in the Proxy Statement was approved, on an advisory basis, based on the following votes:

1 Year		2 Years		3 Years		Abstentions		Broker Non-Votes
40,736,332		8,965		93,260		28,841		2,193,330

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.